Inflammation and genetics are both prominent mechanisms in the pathogenesis of atherosclerosis and arterial thrombosis. Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha. and beta, transforming growth...
-
2002 (v1)PublicationUploaded on: April 14, 2023
-
2005 (v1)Publication
No description
Uploaded on: March 27, 2023 -
2007 (v1)Publication
After acute coronary syndromes,the beneficial effect of aspirin plus clopidogrel (A + C) or aspirin plus dose-adjusted warfarin (A + W) compared with aspirin alone is well established. However, these regimens were never compared. To compare the risk-benefit profile of A + C versus A + W after acute coronary syndromes, major medical databases...
Uploaded on: March 27, 2023 -
2020 (v1)Publication
No description
Uploaded on: February 14, 2024 -
2003 (v1)Publication
No description
Uploaded on: March 27, 2023 -
2008 (v1)Publication
Object: Pexelizumab is a humanized monoclonal antibody inhibiting C5 complement. It has been postulated to improve outcomes in patients undergoing coronary artery bypass surgery and urgent reperfusion therapy for ST elevation myocardial infarction. We aimed at evaluating the risk/benefit profile of pexelizumab (bolus 1 infusion) versus placebo...
Uploaded on: March 27, 2023 -
2005 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2009 (v1)Publication
Background Subgroup analyses of trials enrolling acute coronary syndrome patients suggest that inhibition of glycoprotein IIb/IIIa can improve the outcome of diabetic patients undergoing percutaneous coronary interventions (PCIs), possibly by improving microvascular perfusion. However, the efficacy of small-molecule IIb/IIIa receptor inhibitors...
Uploaded on: April 14, 2023 -
2021 (v1)Publication
No description
Uploaded on: February 13, 2024 -
2021 (v1)Publication
No description
Uploaded on: February 7, 2024